These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
8. Minors come of age: Minor histocompatibility antigens and graft-versus-host disease. Chao NJ Biol Blood Marrow Transplant; 2004 Apr; 10(4):215-23. PubMed ID: 15077220 [TBL] [Abstract][Full Text] [Related]
9. Dimethyl 2,2-dichlorovinyl phosphate (DDVP) markedly inhibits activities of natural killer cells, cytotoxic T lymphocytes and lymphokine-activated killer cells via the Fas-ligand/Fas pathway in perforin-knockout (PKO) mice. Li Q; Nakadai A; Takeda K; Kawada T Toxicology; 2004 Nov; 204(1):41-50. PubMed ID: 15369847 [TBL] [Abstract][Full Text] [Related]
10. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells. Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767 [TBL] [Abstract][Full Text] [Related]
11. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Anderson LD; Mori S; Mann S; Savary CA; Mullen CA Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776 [TBL] [Abstract][Full Text] [Related]
13. Cytolytic pathways in haematopoietic stem-cell transplantation. van den Brink MR; Burakoff SJ Nat Rev Immunol; 2002 Apr; 2(4):273-81. PubMed ID: 12001998 [TBL] [Abstract][Full Text] [Related]
14. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844 [TBL] [Abstract][Full Text] [Related]
15. Cellular mechanisms of lymphocyte-mediated lysis of tumor cells. Arancia G; Malorni W; Donelli G Ann Ist Super Sanita; 1990; 26(3-4):369-84. PubMed ID: 2151107 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand. Kosiewicz MM; Alard P; Liang S; Clark SL Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489 [TBL] [Abstract][Full Text] [Related]
17. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL. Lee SH; Bar-Haim E; Machlenkin A; Goldberger O; Volovitz I; Vadai E; Tzehoval E; Eisenbach L Cancer Gene Ther; 2004 Mar; 11(3):237-48. PubMed ID: 14739939 [TBL] [Abstract][Full Text] [Related]
18. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Verneris MR; Ito M; Baker J; Arshi A; Negrin RS; Shizuru JA Biol Blood Marrow Transplant; 2001; 7(10):532-42. PubMed ID: 11760085 [TBL] [Abstract][Full Text] [Related]
19. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production. Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345 [TBL] [Abstract][Full Text] [Related]